Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sorrento Therapeutics stock | $6.56

Learn how to easily invest in Sorrento Therapeutics stock.

Sorrento Therapeutics Inc is a biotechnology business based in the US. Sorrento Therapeutics shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therapeutics employs 502 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sorrento Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SRNE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sorrento Therapeutics stock price (NASDAQ: SRNE)

Use our graph to track the performance of SRNE stocks over time.

Sorrento Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$6.56
52-week range$6.00 - $17.25
50-day moving average $7.73
200-day moving average $8.10
Wall St. target price$26.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.18

Buy Sorrento Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sorrento Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sorrento Therapeutics price performance over time

Historical closes compared with the close of $6.56 from 2021-10-21

1 week (2021-10-14) -4.65%
1 month (2021-09-18) N/A
3 months (2021-07-22) -25.45%
6 months (2021-04-22) -16.01%
1 year (2020-10-22) -20.77%
2 years (2019-10-22) 334.44%
3 years (2018-10-22) 96.41%
5 years (2016-10-21) 6.93

Sorrento Therapeutics financials

Revenue TTM $51 million
Gross profit TTM $-81,294,000
Return on assets TTM -27.49%
Return on equity TTM -244.23%
Profit margin 0%
Book value $0.64
Market capitalisation $2.1 billion

TTM: trailing 12 months

Shorting Sorrento Therapeutics shares

There are currently 45.7 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 6% up from 43.1 million last month.

There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.

Sorrento Therapeutics's "short interest ratio" (SIR)

Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 4.3 million). Sorrento Therapeutics's SIR currently stands at 10.51. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 10510 shares are currently held short.

However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1705% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 171 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sorrento Therapeutics.

Find out more about how you can short Sorrento Therapeutics stock.

Sorrento Therapeutics share dividends

We're not expecting Sorrento Therapeutics to pay a dividend over the next 12 months.

Have Sorrento Therapeutics's shares ever split?

Sorrento Therapeutics's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.

Sorrento Therapeutics share price volatility

Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as $6 up to $17.25. A popular way to gauge a stock's volatility is its "beta".

SRNE.US volatility(beta: 2.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.4032. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Sorrento Therapeutics overview

Sorrento Therapeutics, Inc. , a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions.

Frequently asked questions

What percentage of Sorrento Therapeutics is owned by insiders or institutions?
Currently 9.129% of Sorrento Therapeutics shares are held by insiders and 26.009% by institutions.
How many people work for Sorrento Therapeutics?
Latest data suggests 502 work at Sorrento Therapeutics.
When does the fiscal year end for Sorrento Therapeutics?
Sorrento Therapeutics's fiscal year ends in December.
Where is Sorrento Therapeutics based?
Sorrento Therapeutics's address is: 4955 Directors Place, San Diego, CA, United States, 92121
What is Sorrento Therapeutics's ISIN number?
Sorrento Therapeutics's international securities identification number is: US83587F2020
What is Sorrento Therapeutics's CUSIP number?
Sorrento Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74838K108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site